Shots:

• The approval is based on P-III ASCLEPIOS I and II studies involves assessing of ofatumumab (20mg- SC) vs Aubagio (14mg oral tablets) in 1882 adults with MS between the ages of 18 and 55 years
• The study resulted in reduction in ARR by 50.5% (0.11 vs. 0.22) and 58.5% (0.10 vs. 0.25)- Risk reduction @3mos. & 6mos. (34.4% & 32.5%)- favorable safety profile- disability improvement at 6 mos.- serum levels of neurofilament light chain (NfL)- and rate of brain volume loss
• Ofatumumab is an anti-CD20 monoclonal antibody (mAb)- self-administered- once-monthly subcutaneous injection in development for RMS with its expected approval in the US and EU in Jun 2020 and Q2'21

Click here to read full press release/ article | Ref: Novartis | Image: Behance